Application of conicity index adjusted total body fat in young adults-a novel method to assess metabolic diseases risk

Yujie Zhang\(^1\), Qiang Zeng\(^2\), Xiaoying Li\(^1\), Pengli Zhu\(^3,4\) & Feng Huang\(^3,4\)

The aim of the study was to evaluate the usefulness of conicity index (CI) adjusted total body fat (TBF), which was defined as TBF/CI, in various metabolic diseases in young adults. A cross-sectional study was carried out in Chinese PLA General Hospital and a total of 1365 young adults (age 20–40 years) who underwent a health check-up examination were finally included in the analysis from February 2016 to 2017. Linear Regression and logistic regression were used to further examine relationship between the index and metabolic diseases. The average age was 34.5 years.

Odds Ratios (ORs) for the risk of metabolic diseases increased from the lowest to highest TBF/CI quartile (all \( P \) trends < 0.001). Young adults with increased TBF/CI had higher risk of hyperhomocysteinemia (Hhcy) (OR = 1.528, 95\% confidence interval = 1.057–2.209). There was a 1.407 increase in the odds of obesity, a 1.112 increase in the odds of hyperlipidemia (HLP) and a 1.094 increase in the odds of diabetes mellitus (DM) per standard deviation (SD) increase in TBF/CI (all \( P < 0.001 \)). TBF/CI showed higher predictive values for obesity, HLP, DM and Hhcy than weight adjusted total body fat (all \( P < 0.001 \)). Young adults with increased TBF/CI had higher ratios of metabolic diseases, which suggested that TBF/CI can be a good indicator and had a close relationship with metabolic diseases.

As market aged with a booming economy and increasing material riches, metabolic diseases are becoming more prevalent among younger group. Scientists have paid more and more attention to the situation, but the evaluation markers were still outdated to assess the risk of metabolic diseases effectively.

Body Composition Analysis, namely bioelectric impedance (BIA), is largely based on the perspective that the electric resistance varies in different human body tissues, thus low-level and safe current which pass through tissues can be detected specifically, quickly and painlessly\(^1\). The technique has drawn more attention over the past years. Weight adjusted total body fat, measured by BIA, was closely associated with many diseases, including cardiovascular diseases, diabetes mellitus (DM) and osteoporosis et al\(^2\).

Previous studies indicated that weight adjusted total body fat may be a better predictor of high blood pressure (HBP), hyperglycemia and hyperlipidemia (HLP), which exemplified cardiovascular risk factors, than body mass index (BMI)\(^3\). However, the value of it remains controversial. Several reports suggested that the trend of it and BMI differed in adults, thus there was no agreement about cut-off points for it to diagnose obesity\(^4\). Furthermore, the application of it is less convenient than BMI. Nevertheless, as the understanding of BIA gradually deepen, appendicular skeletal muscle mass index (ASMI), measured by BIA and then calculated by different formulas, have been used as indicators for the diagnosis of sarcopenia in the elderly people\(^5\). But the formulas of weight adjusted body fat and ASMI could not consider the adipose distribution of participants well, even adjusted by BMI.

Conicity index (CI), which was a good tool to assess fat mass distribution and figure in young adults as previous studies suggested\(^6-7\). Even though CI adjusted indices have potential value in clinical application, little is known about the role of CI adjusted total body fat (TBF), namely TBF/CI, in metabolic diseases assessment. We

\(^1\)Department of Geriatric Cardiology, Chinese PLA General Hospital, Beijing, China. \(^2\)International Medical Center, Chinese PLA General Hospital, Beijing, China. \(^3\)Department of Geriatric Medicine, Fujian Provincial Hospital, Fujian Institute of Clinical Geriatric, Fuzhou, China. \(^4\)Fujian Medical University, Fuzhou, China. Correspondence and requests for materials should be addressed to X.L. (email: xyli301@foxmail.com)
firstly calculated the TBF/CI to determine whether it can be a good indicator and had a close relationship with metabolic diseases in young adults.

**Material and Methods**

**Subjects.** In total, 1365 ambulatory adult subjects aged between 20 and 40 years who underwent a routine health examination including BIA in Chinese PLA General Hospital from February 2016 to 2017 were enrolled. The inclusion criteria were young adults (age 20–40 years) who accepted BIA test. Participants were excluded for any of the following reasons: acute phase of chronic diseases, thyroid disorders, immune diseases, chronic renal failure, anorexia, malignant tumors, gastrointestinal surgery history and incomplete data. All participants were given oral informed consent to take part in the study and their data to be used. The study protocol was approved by the Institutional Review Board of Chinese PLA General Hospital. All methods were performed in accordance with the relevant guidelines and regulations.

**Data Collection and Measurements.** Past history, personal history and family history were collected by trained healthcare providers. All subjects wore light clothes and stood in the upright position without shoes during BIA measurement using a body composition analyzer (X-Scan Plus-II, SELVAS Healthcare Inc., Geumcheon-gu, Seoul, Korea). Body mass, height, waist circumference (WC) and hip circumference (HC) were measured to an accuracy of 0.1 (kg or cm) according to the standard protocol. The 10 h fasting forearm vein blood was obtained in the early morning, and an Architect Ci8200-intergrated system (Abbott Laboratories, USA) was used to detect the level of blood glucose, whole blood glycohemoglobin A1c (HbA1c), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and total plasma homocystein (Hcy). Postprandial glucose was determined at 2 h after the administration of 75 g glucose.

**Diagnostic Definitions.** BMI, waist-hip ratio (WHR), CI, percentage body fat (PBF) were calculated from the following equations:

\[
\begin{align*}
\text{BMI} &= \frac{\text{body mass}}{\text{height}^2}; \\
\text{WHR} &= \frac{\text{WC}}{\text{HC}}; \\
\text{CI} &= \frac{\text{WC}}{(0.109 \times \text{square root of weight/height})}; \\
\text{PBF} &= \frac{\text{TBF}}{\text{body mass}} \times 100.
\end{align*}
\]

In the present study, age, BMI, LDL-C, HbA1c and Hcy were incorporated into continuous metabolic risk variables. Smoking history was defined as daily smoking more than 1 and accumulating 100 or more cigarettes, cigars or pipes for at least 6 months. Obesity was defined as BMI ≥ 28 kg/m² and/or WC in male ≥ 90 cm while in female ≥ 85 cm. HLP was defined as one of following: TC ≥ 5.2 mmol/L, LDL-C ≥ 3.4 mmol/L, HDL-C < 1.0 mmol/L, TG ≥ 1.70 mmol/L or previously diagnosed HLP. DM was defined as fasting blood glucose ≥ 7.0 mmol/L, or blood glucose ≥ 11.1 mmol/L at 2 h after loading glucose, or HbA1c ≥ 6.5%, or previously diagnosed DM. Hyperhomocysteinemia (Hhcyc) was defined as tHcy ≥ 10 μmol/L or currently supplementing folate. All the data were analyzed using the Statistical Package for the Social Sciences, version 22.0 (SPSS, Inc., Chicago, IL, USA). All continuous variables were approximately under normal distribution, and were expressed as mean (standard deviation (SD)). Categorical data were expressed as count (percentage). Linear trend tests were used to evaluate trends of TBF/CI changed in continuous risk variables (e.g. age, BMI, LDL-C, HbA1c and Hcy) and chi-square trend tests were used in assessing odds ratios (ORs) of metabolic diseases varied with increasing quartile of TBF/CI. Moreover, linear regressions without adjustment were constructed to assess association of continuous risk variables with TBF/CI. Logistic Regressions were used to examine ORs of metabolic diseases identified by TBF/CI. Receiver Operator Curves (ROCs) were created to determine the predictive value of different anthropometric indices for various metabolic diseases. A two-sided P value < 0.05 was considered statistically significant.

**Results**

**Participants’ Clinical Characteristics.** The mean age was 34.5 (5.0) years. TBF/CI in all the population, male and female were 14.99 (5.25), 16.07 (5.25), 13.22 (4.76), respectively. 45.1%, 55.4%, 6.4% and 43.4% of young adults had obesity, HLP, diabetes and Hhcyc, separately (Table 1).

**Trends of TBF/CI change in metabolic risk variables.** In whole, Increased TBF/CI was associated with increasing metabolic risk variables (all P trends < 0.001 except age quartile, P trend = 0.010). Besides, the increasing trends were also found in women and men respectively (all P trends < 0.001) except age quartile in men (P trend = 0.115) and tHcy quartile in both men and women (P trend = 0.565 in men and 0.207 in women) (Fig. 1).

**Association of metabolic risk variables with TBF/CI.** Linear regression without adjustment demonstrated that age, BMI, LDL-C, HbA1c and Hhcyc were positively correlated with TBF/CI (β = 0.072 for age, 1.092 for BMI, 1.404 for LDL-C, 1.153 for HbA1c and 0.145 for tHcy; all P < 0.001 except age, P = 0.010) (Fig. 2).

**The odds of TBF/CI in metabolic diseases.** In whole, multivariate-adjusted ORs for the risk of metabolic diseases increased from the lowest to highest TBF/CI quartile (all P trends < 0.001). Young adults with increased TBF/CI had higher risk of Hhcyc (OR = 1.528, 95% confidence interval = 1.057–2.209). There was a 1.407 increase in the odds of obesity, a 1.112 increase in the odds of HLP and a 1.094 increase in the odds of DM per SD increase in TBF/CI adjusted for age, sex and smoking history (all P < 0.001).
Besides, the increasing ORs for the risk of Obesity, HLP, DM were also found in women and men respectively (all P trends < 0.001 except P trend for DM in men = 0.008 and 0.005 in women). Men with increased TBF/CI had higher risk of Hhcy (OR = 1.703, 95% confidence interval = 1.072–2.706). There was a 1.528 increase in the Total (n = 1365) male (n = 846) female (n = 519)

|                  | Total (n = 1365) | male (n = 846) | female (n = 519) |
|------------------|------------------|---------------|-----------------|
| Age (years)      | 34.5 (5.0)       | 34.8 (4.8)    | 33.9 (5.3)      |
| Men (n, %)       | 846 (62.0)       | —             | —               |
| Smoking history (n, %) | 447 (32.7)      | 426 (50.4)    | 21 (4.0)        |
| BMI (kg/m²)      | 24.56 (4.39)     | 26.32 (3.90)  | 21.69 (3.52)    |
| WHR              | 0.84 (0.08)      | 0.89 (0.06)   | 0.76 (0.05)     |
| HDL-C (mmol/L)   | 1.30 (0.39)      | 1.14 (0.30)   | 1.57 (0.39)     |
| LDL-C (mmol/L)   | 3.03 (0.79)      | 3.18 (0.82)   | 2.80 (0.68)     |
| TC (mmol/L)      | 4.66 (1.01)      | 4.78 (1.12)   | 4.46 (0.77)     |
| HbA1c (%)        | 5.41 (0.72)      | 5.51 (0.85)   | 5.25 (0.38)     |
| tHcy (μmol/L)    | 10.90 (6.29)     | 12.77 (6.75)  | 7.68 (3.58)     |
| TBF/CI (kg²/m⁴)  | 14.99 (5.25)     | 16.07 (5.25)  | 13.22 (4.76)    |
| Obesity (n, %)   | 615 (45.1)       | 513 (60.6)    | 102 (19.7)      |
| HLP (n, %)       | 756 (55.4)       | 605 (75.1)    | 151 (29.1)      |
| DM (n, %)        | 87 (6.4)         | 74 (8.7)      | 13 (2.5)        |
| Hhcy (n, %)      | 592 (43.4)       | 500 (59.1)    | 92 (17.7)       |

Table 1. Participants' clinical characteristics. Continuous data were shown as mean (SD) and categorical data were n (%). BMI: body mass index; WHR: waist-hip ratio; HDL-C: high-density lipoprotein-cholesterol; LDL-C: low-density lipoprotein-cholesterol; TC: total cholesterol; HbA1c: hemoglobin A1c; tHcy: total homocystein; TBF/CI: total body fat/conicity index; HLP: hyperlipidemia; DM: diabetes mellitus; Hhcy: hyperhomocysteinemia.

Figure 1. Trends of TBF/CI change in different metabolic risk variables. TBF/CI: total body fat/conicity index; BMI: body mass index; LDL-C: low-density lipoprotein-cholesterol; HbA1c: hemoglobin A1c; tHcy: total homocystein. Age: Quartile1: 20–33 years, Quartile2: 33–38 years, Quartile3: 38–40 years; BMI: Quartile1: < 21.40 kg/m², Quartile2: 21.40–24.20 kg/m², Quartile3: 24.20–27.30 kg/m², Quartile4: > 27.30 kg/m²; LDL-C: Quartile1: < 2.48 mmol/L, Quartile2: 2.48–2.98 mmol/L, Quartile3: 2.98–3.53 mmol/L, Quartile4: > 3.53 mmol/L; HbA1c: Quartile1: < 5.10%, Quartile2: 5.10–5.30%, Quartile3: 5.30–5.50%, Quartile4: > 5.50%; tHcy: Quartile1: < 6.93 μmol/L, Quartile2: 6.93–9.25 μmol/L, Quartile3: 9.25–12.49 μmol/L, Quartile4: > 12.49 μmol/L. Test for linear trend: P trend for age in whole = 0.010, other P trends < 0.001.
odds of obesity in men, a 1.264 increase in women per SD increase in TBF/CI after adjustment (all
P < 0.001). A 1.159 increase in the odds of HLP in men (P < 0.001) and a 1.055 increase in women (P = 0.008) were found as one TBF/CI unit increasing. The odds of DM increased 1.098 in men (P < 0.001) and 1.090 in women (P = 0.046) with TBF/CI changed per SD (Table 2).

Table 2. The odds of TBF/CI in metabolic diseases. Abbreviations: TBF/CI: total body fat/conicity index; HLP: hyperlipidemia; DM: diabetes mellitus; Hhcy: hyperhomocysteinemia. TBF/CI: Quartile1: < 11.44 kg3/2/m3/2, Quartile2: 11.44–14.51 kg3/2/m3/2, Quartile3: 14.51–17.87 kg3/2/m3/2, Quartile4: > 17.87 kg3/2/m3/2. Each of the independent variables in whole population has been adjusted for age, sex and smoking history. The variables in men and women have been adjusted for age and smoking history. Test for linear trend: *P trend < 0.05, **P trend < 0.001; Logistic Regression: †P < 0.05, ††P < 0.001.

Predictive values of different anthropometric indices for various metabolic diseases. TBF/CI (Area Under Curve (AUC) = 0.845) showed a higher predictive value for obesity than WHR (AUC = 0.841) and PBF (AUC = 0.771), but lower than BMI (AUC = 0.921) (all P < 0.001). In HLP, DM and Hhcy, TBF/CI (AUC = 0.694 for HLP, 0.673 for DM and 0.587 for Hhcy) also displayed higher predictive values than PBF (AUC = 0.597 for HLP and 0.616 for DM, but AUC was not available to Hhcy because of P = 0.648), but lower than both BMI (AUC = 0.746 for HLP, 0.731 for DM and 0.643 for Hhcy) and WHR (AUC = 0.769 for HLP, 0.721 for DM and 0.682 for Hhcy) (all P < 0.001, Fig. 3). Cut-off value of TBF/CI for obesity was 14.91 kg3/2/m3/2 with 0.764 sensitivity and 0.784 specificity, for HLP was 13.86 kg3/2/m3/2 with 0.683 sensitivity and 0.601 specificity, for DM was 14.95 kg3/2/m3/2 with 0.736 sensitivity and 0.559 specificity and for Hhcy was 13.87 kg3/2/m3/2 with 0.653 sensitivity and 0.509 specificity.
Discussion

Our study reported for the first time that the usefulness of TBF/CI in various metabolic diseases in young adults. CI is an useful and accuracy tool to evaluate the distribution of fat mass. As BMI cannot distinguish fat mass and lean mass clearly and its prediction is prone to be disturbed by the difference of samples in adipose distribution and body build, use of the BMI as a predictor for body fatness has been criticized. However, TBF/CI, could represent the condition of total body fat well after balances individual adipose distribution. WHR, another anthropometric index, is not universally acknowledged as an accurate procedure to identify individuals at risk for metabolic syndrome. As seen from in our study, TBF/CI showed a significant value. Linear Regression and logistic regression seperately demonstrated that TBF/CI had a higher correlation with tHcy and was in closer relatation with Hhcy. Moreover, as young adults with increased BMI did not display higher risk of Hhcy (P = 0.956, data not shown), TBF/CI can better evaluate the risk of Hhcy.

A cross-sectional study carried out in American middle age population demonstrated that intramuscular fat was associated with HLP risk. As mentioned above, we observed that the risk of HLP increased with added TBF/CI as well.

Even before-mentioned studies have pointed out that there were close ties between body composition and metabolic risk factors, controversy has emerged till now regarding the relevance between body fat and abnormal glucose metabolism. Canadian aged 20–69 and consisted of overweight or obesity were enrolled in a cross-sectional study by Kuk JL et al., which pinpointed that volatile fatty acid instead of whole-body skeletal muscle mass measured by magnetic resonance imaging was a significant predictor of abnormal glucose metabolism. Nonetheless, Son JW et al. did a prospective cohort study (follow-up 2 years) in South Korean community residents aged 40–69, which exhibited that a hazard ratio of 1.35 increase for the risk of developing type 2 diabetes per SD decrease in ASMI using multi-frequency BIA that strongly consistent with dual-emergency x-ray absorptiometry (DXA). In our present work, there were a 1.094 increase in the odds of DM per SD increase in TBF/CI. The results suggested that the diabetes risk increased with augmented TBF/CI in young adults and BIA maybe a viable, portable and accessible instrument for community and clinic-based assessment recommended by the
Asian Working Group of Sarcopenia (AWGS)

Disparate measurements in heterogeneous ethnic groups may account for the argumenative results.

Accordingly, another association between body fat and tHcy has remained controversial. Battezzati A et al. explicated that tHcy was positively related to fat-free mass and lean body mass in middle-aged Italian by a cross-sectional study. Whereas another study targeting Chinese hypertension population aged 45–75 years explicated that nearly 20% decrease in OR for Hhcy in subjects with high physical activities. A significant positive correlation between tHcy and TBF/CI were displayed in our study. There may be two possible explanations. For one thing, attention has been paid to animal protein intake accompanied with fat intake which may lead to the ignorance of vegetable consumption in young’s diet. As is known to us, vegetable was a vital and natural source of folate and vitamin B complex, and the lack of which could cause Hhcy. For another, the young was fit in a stage of good absorption and vigorous synthetic metabolism. Age, various health status, diet structure and surroundings may contribute to the disputable results.

Generally speaking, TBF/CI has its irreplaceable advantages. Firstly, compared with biochemical test, TBF/CI was non-invasive. It was convenient and costless for early metabolic syndrome assessment. Secondly, seen from our study, CI adjusted TBF showed higher predictive values for metabolic diseases than traditional definition, namely weight adjusted total body fat. Even the AUC of TBF/CI was less than the obesity gold standard-BMI, TBF/CI showed a higher predictive value for obesity than WHR. The function of TBF/CI is worth of further exploration in the future, maybe it could replace WHR sometimes especially in some patients who could not measure hip circumference for some special causes, like hip bed sore. Thirdly, the AUCs of TBF/CI were nearly between 0.7 and 0.9, which manifested median value in assessing metabolic diseases.

However, as a cross-sectional study, the work had inevitable limitations. Firstly, biases were unavoidable since it was a single center research specific to check-up population. Secondly, we did not evaluate hormone level and nutritional status that could be confounding factors that affected TBF/CI. Last but not least, we only discussed the relationship between TBF/CI and metabolic diseases. So cause-and-effect relationship could not be demonstrated in the study. Therefore, a large and longitudinal cohort is warranted to further analyze the association between TBF/CI and metabolic diseases.

In conclusion, Young adults with increased TBF/CI had higher ratios of metabolic diseases, which suggested that TBF/CI can be a good indicator and exhibited a close relationship with metabolic diseases.

References
1. Zeng, Q., Dong, S. Y., Sun, X. N., Xie, J. & Cui, Y. Percent body fat is a better predictor of cardiovascular risk factors than body mass index. *Braz J Med Biol Res*. 45, 591–600 (2012).
2. Zeng, Q., Sun, X. N., Fan, L. & Ye, F. Correlation of body composition with cardiac function and arterial compliance. *Clin Exp Pharmacol Physiol*. 35, 78–82 (2008).
3. Flegal, K. M. et al. Comparisons of percentage body fat, body mass index, waist circumference, and waist-to-hip ratio in adults. *Am J Clin Nutr*. 89, 500–8 (2009).
4. Fielding, R. A. et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. *J Am Med Dir Assoc*. 12, 249–56 (2011).
5. Kim, T. N. et al. Association of low muscle mass and combined low muscle mass and visceral obesity with low cardiorespiratory fitness. *PLoS One*. 9, e100118 (2014).
6. Burrows, R. et al. High cardiometabolic risk in healthy Chilean adolescents: associations with anthropometric, biological and lifestyle factors. *Public Health Nutr*. 19, 486–93 (2016).
7. Santtila, M., Häkkinen, K., Nindl, B. C. & Kyröläinen, H. Cardiovascular and neuromuscular performance responses induced by 8 weeks of basic training followed by 8 weeks of specialized military training. *J Strength Cond Res*. 26, 745–51 (2012).
8. Lohman, T. G., Roche, A. F. & Martorell, R. Anthropometric standardization reference manual (abridged edition). *Champaign, Illinois: Human Kinetics*. 44–46 (1988).
9. National Center of Cardiovascular Diseases, China. Report on Cardiovascular Diseases in China (2010). *Encyclopedia of China Publishing House*. 13–5 (2011).
10. Sub-Committee of Obesity of Chinese Society of Endocrinology of Chinese Medical Association. Chinese expert consensus on prevention and treatment of obesity in adults. *Chin J Endocrinol Metab*. 27, 711–7 (2011).
11. Joint Committee for Developing Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults. Chinese Guidelines on prevention and treatment of dyslipidemia in adults (2016 revised edition). *Chin Circ J*. 31, 937–53 (2016).
12. Chinese Society of Diabetes. Chinese Guidelines on prevention and treatment of type 2 diabetes (2013 edition). *Chin J Diabetes Mellitus*. 6, 447–98 (2014).
13. Sun, Y. et al. Use of serum homocysteine to predict stroke, coronary heart disease and death in ethnic Chinese. 12-year prospective cohort study. *Circ J*. 73, 1423–30 (2009).
14. Stanger, O. et al. DACH-LIGA homocystein (german, austrian and swiss homocystein society): consensus paper on the rational clinical use of homocystein, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. *Clin Chem Lab Med*. 41, 1392–403 (2003).
15. Lei, S. F. et al. Relationship of total body fatness and five anthropometric indices in Chinese aged 20–40 years: different effects of age and gender. *Eur J Clin Nutr*. 60, 511–8 (2006).
16. Perona, J. S., Schmidt-RioValle, J., Rueda-Medina, B., Correa-Rodríguez, M. & González-Jiménez, E. Waist circumference shows the highest predictive value for metabolic syndrome, and waist-to-hip ratio for its components, in Spanish adolescents. *Nutr Res*. 45, 38–45 (2017).
17. Therkelsen, K. E. et al. Intramuscular fat and associations with metabolic risk factors in the Framingham Heart Study. *Arterioscler Thromb Vasc Biol*. 33, 863–70 (2013).
18. Kuk, J. L., Kilpatrick, K., Davidson, L. E., Hudson, R. & Ross, R. Whole-body skeletal muscle mass is not related to glucose tolerance or insulin sensitivity in overweight and obese men and women. *Appl Physiol Nutr Metab*. 33, 769–74 (2008).
19. Son, J. W. et al. Low muscle mass and risk of type 2 diabetes in middle-aged and older adults: findings from the KoGES. *Diabetologia*. 60, 865–872 (2017).
20. Chen, L. K. et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. *J Am Med Dir Assoc*. 15, 95–101 (2014).
21. Goodpaster, B. H., He, J., Watkins, S. & Kelly, D. E. Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. *J Clin Endocrinol Metab*. 86, 5755–61 (2001).
22. Battezzati, A., Bertoli, S., San Romerio, A. S. & Testolin, G. Body composition: an important determinant of homocysteine and methionine concentrations in healthy individuals. *Nutr Metab Cardiovasc Dis* 17, 525–34 (2007).

23. Wang, Y. *et al.* Prevalence of hyperhomocysteinaemia and its major determinants in rural Chinese hypertensive patients aged 45–75 years. *Br J Nutr* 109, 1284–93 (2013).

24. Shavlakadze, T. & Grounds, M. Of bears, frogs, meat, mice and men: complexity of factors affecting skeletal muscle mass and fat. *Bioessays.* 28, 994–1009 (2006).

25. Guilliams, T. G. Homocysteine - A Risk Factor for Vascular Diseases: Guidelines for the Clinical Practice. *JANA.* 7, 11–24 (2004).

26. Taylor, R. W., Jones, I. E., Williams, S. M. & Goulding, A. Evaluation of waist circumference, waist-to-hip ratio, and the conicity index as screening tools for high trunk fat mass, as measured by dual-energy X-ray absorptiometry, in children aged 3–19 y. *Am J Clin Nutr.* 72, 490–5 (2000).

**Author Contributions**

Z.Y. participated in the design of the study and drafted the manuscript. H.F. helped the interpretation of data and the statistical analysis. L.X., Z.Q. and Z.P. contributed to the conception of the study design and participated in its design and are the guarantors of the work. Z.Q. contributed to the data collection process. All authors have read and approved the final manuscript.

**Additional Information**

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018